Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 1.00 |
| ▸ | ITGAV | P06756 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.63 |
| ▸ | DUSP26 | Q9BV47 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717775 | 0.92 | ITGB3 (0.85) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL12717765 | 0.85 | PTP4A3 (0.83) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL20846416 | 0.79 | PTP4A3 (0.70) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL30117305 | 0.77 | PTP4A3 (1.00) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL12717766 | 0.74 | PTPN1 (0.60) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL12177391 | 0.72 | PTPN2 (0.57) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL14426562 | 0.70 | PSMB8 (0.75) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL12177449 | 0.69 | ALDH1A1 (0.61) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL12177489 | 0.69 | ALDH1A1 (0.57) | ITGB3ITGAVKDM4EMEN1ALDH1A1 | |
| SCHEMBL12177501 | 0.68 | PTPN2 (0.61) | ITGB3ITGAVMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249191-A1 | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2014-09-04 | — | — | US | disclosed |
| US-20140249191-A1 | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2014-09-04 | — | — | US | disclosed |
| US-20130102645-A1 | Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057183-A1 | COMPOSITIONS FOR CONTROLLING VASCULARIZATION IN OPHTHALMOLOGICAL AND DERMATOLOGICAL DISEASES | AVIENNE PHARMACEUTICALS GMBH (AT) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102645-A1 | Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2013-04-25 | — | — | US | disclosed |
| US-7928113-B2 | Integrin-binding small molecules | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928113-B2 | Integrin-binding small molecules | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20070155750-A1 | INTEGRIN-BINDING SMALL MOLECULES | USC STEVENS-UNIVERSITY OF SOUTHERN CALIFORNIA | 2007-07-05 | — | — | US | disclosed |
| US-20070155750-A1 | INTEGRIN-BINDING SMALL MOLECULES | USC STEVENS-UNIVERSITY OF SOUTHERN CALIFORNIA | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102645-A1 | Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases | KDR, REN, FLT1 | ITGB3 2036/4885ITGAV 1978/4885KDM4E 4397/4885 |
| US-20070155750-A1 | INTEGRIN-BINDING SMALL MOLECULES | ITGB3, ITGB5, ITGA2B | ITGB3 1/4885ITGAV 7/4885KDM4E 3949/4885 |
| US-20140249191-A1 | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases | FLT1, KDR, FLT4 | ITGB3 2012/4885ITGAV 1557/4885KDM4E 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.